Hyperbaric oxygen therapy is a treatment method that involves breathing in pure oxygen inside a pressurized chamber. It has been used for various medical conditions, including for wound healing and to treat conditions caused by a lack of oxygen to the tissues.
Crohn's, some studies have suggested that may be safe and potentially effective in treating the condition. Crohn's is a type of Crohn's disease characterized by the formation of fistulas, or abnormal connections between the bowel and other organs or the skin. These fistulas can cause significant discomfort and complications and can be difficult to treat.
a study published in the Journal of Crohn's and Colitis in 2018 found that was effective in reducing the number and size of fistulas in patients with Crohn's disease. The study involved 24 patients with Crohn's who received a total of 40 sessions. The results showed that the number of fistulas decreased by an average of 50% and the size of the fistulas decreased by an average of 40%.
Another study published in the Journal of Gastrointestinal Surgery in 2017 found that was effective in treating Crohn's disease-related fistulas. The study involved 20 patients with Crohn's disease who had fistulas that were not responding to conventional treatment. The patients received a total of 40 sessions. The results showed that the fistulas were closed in 80% of the patients, and there were no serious side effects reported.
While these studies suggest that may be a safe and effective treatment for Crohn's, more research is needed to confirm these findings. It is important to note that hyperbaric oxygen therapy is not yet considered a standard treatment for Crohn's and should be used under the guidance of a qualified healthcare professional.
In summary, some studies have suggested that hyperbaric oxygen therapy may be safe and potentially effective in treating fistulizing Crohn's. However, more research is needed to confirm these findings, and Hyperbaric oxygen therapy is not yet considered a standard treatment for Crohn's, it should be used under the guidance of a qualified healthcare professional.
The researchers also analyzed outcomes based on the type of fistula. They reported that in 15 studies, the clinical response was seen in 115 of 130 patients diagnosed with perianal fistulas and that in 13 studies, clinical remission was achieved in 68 of 113 patients with perianal fistulas. In 13 studies where patients who had undergone J-pouch surgery were excluded, the rate of clinical response was seen in 89 of 100 cases, while clinical remissions were observed in 50 of 83 cases (n=11 studies).
Among patients who were diagnosed with enterocutaneous fistulas, clinical response was observed in 21 of 25 cases (n=5 studies) while clinical remission was observed in 14 of 19 cases (n=4 studies).
And among patients who were diagnosed with l fistulas, clinical response and remission were seen in four of 14 cases (n=5 studies). Dokmak noted that fistulas were the fistula type least responsive to hyperbaric oxygen therapy."
The overall clinical response was 89%, 84%, and 29% for perianal, enterocutaneous, and fistulas, respectively, according to the researchers.
They looked at clinical response rates based on whether patients were treated in the biologic or pre-biologic setting, but there were no significant differences in the time analysis, except for patients with l fistula who appeared to do better in the pre-biologic era with a 52% clinical response rate and a 25% response rate in the biologic era.
You must be logged in to post a comment.